‘Modest support’ for PFS as OS surrogate in HER2-positive metastatic breast cancer

Progression-free survival only moderately correlates with overall survival at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with HER2-targeted agents, say researchers.
Source: MedWire News - Category: Consumer Health News Tags: Breast cancer Source Type: news